Site Search
Professionals 12 Results
Services 7 Results
Focus Area
Our representation of life science companies typically spans the full lifecycle of the business, from advising founders on incorporation through all stages of financings, in-licenses, day-to-day commercial contract issues, bet-the-company strategic collaborations, M&As and IPOs.
Focus Area
We help emerging growth companies design and administer executive compensation plans that align with their specific goals and attract top talent. We bring deep technical expertise and a customized approach to ensure these plans are strategically sound for the long term.
Focus Area
We don’t “over-lawyer” deals. We have a commercial mindset. We help investors make optimal risk-adjusted business decisions. Our deep knowledge of the venture capital and growth equity markets and how these funds are formed and operate allows us to fluently speak the language of GPs, fund COOs and VCGCs. We translate our extensive experience into actionable market insights. Our team has a laser focus on the needs of venture capital and growth equity funds, and deliver the right amount of service for the type of investment, from pre-seed to pre-IPO.
Insights 359 Results
Client News
|May 14, 2026
Nectar Social Raises $30 Million Series A
Nectar Social announces its $30 million Series A financing led by Menlo Ventures with participation from True Ventures, Google Ventures, and Gwyneth Paltrow’s Kinship Ventures.
Client News
|May 12, 2026
Thrive Capital Leads Isomorphic Labs’ $2.1 Billion Series B
Thrive Capital led the $2.1 billion Series B financing of Isomorphic Labs, an AI-first drug design and development company.
Public Ventures
|May 6, 2026
SEC Proposes Optional Semiannual Financial Reporting Framework for Public Companies
“Today’s proposal is just the first step of the larger, comprehensive effort to review and reshape the current SEC rules governing public companies with respect to their ongoing reporting obligations and their ability to raise capital in the public markets. Over the next few months, I expect that the Commission will be considering a series of proposals that, if adopted, will not only redefine what it means to be a public company, but will make being public attractive again.”
Client News
|May 3, 2026
Dalus Capital Invests in Alkemio $2 Million Financing
Gunderson Dettmer represented client Dalus Capital in the $2 million pre-seed financing of Alkemio, a Buenos Aires-based company focused on developing a deep-tech modular low-emission refining system for on-site production of high-purity rare earth element oxides.
More Results 7 Results
Location
China represents the world’s second largest market for venture capital investing. In 2012, Gunderson Dettmer launched its first office outside of the U.S. in Beijing. The inception of our China practice was a significant milestone in Gunderson Dettmer’s strategic expansion into key venture markets internationally.
Careers